The estimated Net Worth of Franklin Stuart Friedman is at least $256 mil dollars as of 8 June 2023. Franklin Friedman owns over 10,000 units of Deciphera Pharmaceuticals Inc stock worth over $255,900 and over the last 5 years Franklin sold DCPH stock worth over $0.
Franklin has made over 1 trades of the Deciphera Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Franklin bought 10,000 units of DCPH stock worth $138,800 on 8 June 2023.
The largest trade Franklin's ever made was buying 10,000 units of Deciphera Pharmaceuticals Inc stock on 8 June 2023 worth over $138,800. On average, Franklin trades about 909 units every 0 days since 2019. As of 8 June 2023 Franklin still owns at least 10,000 units of Deciphera Pharmaceuticals Inc stock.
You can see the complete history of Franklin Friedman stock trades at the bottom of the page.
Franklin's mailing address filed with the SEC is C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM, MA, 02451.
Over the last 7 years, insiders at Deciphera Pharmaceuticals Inc have traded over $25,274,872 worth of Deciphera Pharmaceuticals Inc stock and bought 3,916,644 units worth $57,831,028 . The most active insiders traders include Liam Ratcliffe, Associates Llc Brightstar y Ron Squarer. On average, Deciphera Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $1,218,775. The most recent stock trade was executed by Thomas Patrick Kelly on 15 February 2024, trading 3,010 units of DCPH stock currently worth $47,016.
deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.
Deciphera Pharmaceuticals Inc executives and other stock owners filed with the SEC include: